The product will be offered as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—enabling flexible once-weekly dosing
Sun Pharmaceutical Industries Ltd. has received approval from the <a href="https://absafricatv.com/amazon-will-launch-its-satellite-internet-in-south-africa-seemingly-beating-musk-in-his-homeland/" title="Amazon will launch its satellite internet in South Africa, seemingly beating Musk in his homeland”>South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus, to be used alongside diet and exercise.
The company plans to launch the product in South Africa in the coming days. It will be offered as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—enabling flexible once-weekly dosing.
With this approval, South Africa becomes the second market after India where Sun Pharma has secured regulatory clearance for a generic semaglutide product, underscoring the company’s growing capabilities in developing complex generic medicines for global markets.
Aalok Shanghvi, Chief Operating Officer, Sun Pharma, said, “South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals.”
The approval comes as South Africa grapples with a rising burden of type 2 diabetes, fuelled by rapid urbanisation, lifestyle changes, and increasing obesity rates. Expanding access to affordable, evidence-based therapies such as generic semaglutide is expected to support better disease management while easing pressure on the country’s healthcare system.
The latest regulatory clearance further strengthens Sun Pharma’s diabetes portfolio and reinforces its strategy of expanding access to high-quality, affordable generic medicines in international markets.
Upcoming E-conference
Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma
Other Related stories
OneSource Specialty Pharma, Formycon forge strategic manufacturing partnership for biosimilars
Lupin ranked among India’s top 14 employers by Great Place To Work India
ten23 health, dsm-firmenich collaborate to expand excipient options for injectable biologics
Interviews
India’s clinical research has moved beyond trial execution: Karan Daftary, Managing Director, SIRO Clintech
Needle-free drug delivery enhances comfort, compliance and treatment outcomes: Sarvesh Mutha, Managing Director, IntegriMedical
Cognitively impaired children who refused to give up inspired me: Dr. Pradipta Biswas, Associate Professor, Indian Institute of Science
Appointments
Biological E appoints Anumeha Srivastava as CEO of digital health JV
Bayer appoints Simon Rosof as Head of Asia Pacific Pharmaceuticals
Alkem Labs appoints Shivaditya Banerjee as Senior Vice President – Human Resources
Startup
eNLife Research raises Rs. 6 crore to build AI-powered blood test for early Alzheimer’s detection
IHH Healthcare and Fortis announce winners of inaugural healthcare startup accelerator
<img src="https://absafricatv.com/wp-content/uploads/2026/07/SuperLiving_195_291-1.jpeg" alt="SuperLiving raises $7 million in Series A to scale AI-powered preventive health platform”>
SuperLiving raises $7 million in Series A to scale AI-powered preventive health platform
Digitization
Fischer Medical strengthens AI-led drug discovery push through Nanyang Biologics partnership
THIP partners with ISSRF to launch evidence-based digital education programme on Endometriosis
Roche to set up second digital tech hub in India at Hyderabad
Upcoming E-conference
July 17, 2026
Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma
Latest Stories
Lupin ranked among India’s top 14 employers by Great Place To Work India
Cadila reaffirms commitment to patient safety following regulatory communication on Aciloc
NATCO Pharma raises stake in South Africa’s Adcock Ingram to 49%
FDA grants De Novo authorisation to Claria Medical’s hysterectomy tissue extraction system
White Papers
Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants
Implementing a digital transformation in chemical operations to maximize profitability
The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation
The guiding role of fluidized and spouted bed technologies in particle building processes
Opinion
Ambient clinical intelligence is reshaping future of healthcare delivery: Rustom Lawyer, Co-Founder & CEO, Augnito
NCAHP Act has built backbone of India’s healthcare workforce: Nalin Saluja, Co-Founder & CTO, Virohan
Interviews
India’s clinical research has moved beyond trial execution: Karan Daftary, Managing Director, SIRO Clintech
Karan DaftaryManaging Director, SIRO Clintech
Needle-free drug delivery enhances comfort, compliance and treatment outcomes: Sarvesh Mutha, Managing Director, IntegriMedical
Sarvesh MuthaManaging Director, IntegriMedical
Cognitively impaired children who refused to give up inspired me: Dr. Pradipta Biswas, Associate Professor, Indian Institute of Science
Packaging
Amcor joins forces with Kelpi to push bio-based barrier coatings for fiber packaging
Clariant boosts high-speed packaging efficiency with expanded continuous strip desiccant reels
